Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam
- PMID: 3582473
- DOI: 10.1007/BF00609964
Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam
Abstract
Piroxicam (20 mg once daily) was administered orally to six healthy young volunteers for 15 days. Trough steady-state levels of piroxicam and 5'-hydroxypiroxicam were 5.5 and 1.2 micrograms/ml, respectively. Piroxicam's plasma half-life (54.9 h) was significantly shorter than that of 5'-hydroxypiroxicam (70.5 h). Percent unbound piroxicam and 5'-hydroxypiroxicam in plasma at steady-state averaged 1.10 and 8.07 respectively. An average of 25.2% of the dose was recovered in urine as 5'-hydroxypiroxicam; approximately two-thirds (17.2%) in the form of the glucuronide conjugate. Average steady-state plasma levels (Css) of piroxicam (7.0 micrograms/ml) were significantly higher than predicted from a previously reported single dose study (5.3 micrograms/ml).
Similar articles
-
Clinical pharmacokinetics of tenoxicam.Clin Pharmacokinet. 1994 Jan;26(1):16-43. doi: 10.2165/00003088-199426010-00003. Clin Pharmacokinet. 1994. PMID: 8137596 Review.
-
The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.Br J Clin Pharmacol. 1994 Jan;37(1):1-5. doi: 10.1111/j.1365-2125.1994.tb04230.x. Br J Clin Pharmacol. 1994. PMID: 8148211 Free PMC article.
-
Quantification of piroxicam and 5'-hydroxypiroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration.J Pharm Biomed Anal. 2016 Feb 20;120:212-20. doi: 10.1016/j.jpba.2015.12.042. Epub 2015 Dec 28. J Pharm Biomed Anal. 2016. PMID: 26760238
-
The effect of age on piroxicam disposition in rheumatoid arthritis.J Rheumatol. 1988;15(5):757-63. J Rheumatol. 1988. PMID: 3172091
-
Clinical pharmacokinetics of lornoxicam. A short half-life oxicam.Clin Pharmacokinet. 1998 Jun;34(6):421-8. doi: 10.2165/00003088-199834060-00001. Clin Pharmacokinet. 1998. PMID: 9646006 Review.
Cited by
-
Analysis of piroxicam in pharmaceutical formulation and human urine by dispersive liquid-liquid microextraction combined with spectrophotometry.Adv Pharm Bull. 2013;3(1):37-44. doi: 10.5681/apb.2013.007. Epub 2013 Feb 7. Adv Pharm Bull. 2013. PMID: 24312810 Free PMC article.
-
Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms.Vet Clin North Am Small Anim Pract. 2013 Sep;43(5):1039-54. doi: 10.1016/j.cvsm.2013.05.002. Vet Clin North Am Small Anim Pract. 2013. PMID: 23890237 Free PMC article. Review.
-
Plasma tenoxicam concentrations after single and multiple oral doses.Eur J Drug Metab Pharmacokinet. 1989 Jan-Mar;14(1):23-7. doi: 10.1007/BF03190838. Eur J Drug Metab Pharmacokinet. 1989. PMID: 2788089
-
Clinical pharmacokinetics of tenoxicam.Clin Pharmacokinet. 1994 Jan;26(1):16-43. doi: 10.2165/00003088-199426010-00003. Clin Pharmacokinet. 1994. PMID: 8137596 Review.
-
Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.Eur J Clin Pharmacol. 1995;47(6):531-6. doi: 10.1007/BF00193707. Eur J Clin Pharmacol. 1995. PMID: 7768257 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases